Sulfonylureas and pioglitazone prolonged survival in mice with SOD1 gene deficiencies [17], but a randomized, double-blind, placebo-controlled ALS trial of riluzole plus pioglitazone was terminated early due to ineffectiveness [18]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.